B-CELL NON-HODGKIN LYMPHOMA (NHL)
Clinical trials for B-CELL NON-HODGKIN LYMPHOMA (NHL) explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON-HODGKIN LYMPHOMA (NHL) trials appear
Sign up with your email to follow new studies for B-CELL NON-HODGKIN LYMPHOMA (NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered cells take on hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem …
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA (NHL)
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cell therapy CT1182 takes on tough lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Last-Resort drug made available for lymphoma patients
Disease control AVAILABLEThis program provides compassionate use of odronextamab for people with relapsed or refractory follicular lymphoma, diffuse large B-cell lymphoma, or other B-cell non-Hodgkin lymphomas who have no other treatment options. Odronextamab is a drug that helps the immune system attack…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA (NHL)
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC